In this issue:
Reduced vs maximum tolerated methotrexate dose + adalimumab in RA
Safety of biological and targeted synthetic DMARDs for RA
Ustekinumab vs TNF inhibitors in PsA
Air pollutants and initiation of biological therapy for AS
Upadacitinib or adalimumab for RA
Brodalumab in axial spondyloarthritis
Sustained glucocorticoid tapering with anifrolumab
Long-term persistence with golimumab for RA
Optimisation of tocilizumab therapy in giant cell arteritis
Please login below to download this issue (PDF)